Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2006-04-18 | Martin D. Cleary was appointed as a member of our board of directors in October 2005. Since February 2003, he has served as the President and Chief Executive Officer of Juvaris Biotherapeutics, Inc., a company engaged in the development of therapeutic vaccines for cancer and infectious diseases. From September 1999 to May 2002, he served as the President and Chief Executive Officer of Genteric, Inc., a company engaged in non-viral gene delivery. Mr. Cleary received a B.S. in accounting from Rutgers University in 1971, and a certificate in international studies from Columbia University in 1973. |
| 2007-04-20 | Martin D. Cleary was appointed as a member of our Board of Directors in October 2005. ... Mr. Cleary's director compensation was $46,150 in 2006. |
| 2008-04-15 | Martin D. Cleary was appointed as a member of our Board of Directors in October 2005. The compensation table shows he earned $43,800 in 2007. |
| 2009-04-17 | Martin D. Cleary was appointed as a member of our Board of Directors in October 2005. From February 2003 through March 2008, he served as the President and Chief Executive Officer of Juvaris Biotherapeutics, Inc., a company engaged in the development of therapeutic vaccines for cancer and infectious diseases. He remains the Chairman of the Board of Directors of Juvaris Biotherapeutics, Inc. and continues to be engaged with that company. From September 1999 to May 2002, he served as the President and Chief Executive Officer of Genteric, Inc., a company engaged in non-viral gene delivery. Mr. Cleary received a B.S. in accounting from Rutgers University in 1971, and a certificate in international studies from Columbia University in 1973. |
| 2010-03-25 | Martin D. Cleary was appointed as a member of our Board of Directors in October 2005. The current members of our audit committee are Messrs. Braginsky, Cleary and Lufkin. The current members of our compensation committee are Messrs. Castleman, Braginsky and Chryssis. For 2009 our non-employee directors received an annual fee of $10,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. The chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2009, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant. Total compensation for Mr. Cleary was $69,375. |
| 2011-03-24 | Martin D. Cleary was appointed as a member of our Board of Directors in October 2005. For 2010 our non-employee directors received an annual fee of $15,000 for serving as directors and an additional $500 per meeting for each full board or committee meeting attended. In addition, the chairman of each of our compensation committee, our audit committee and our nominating committee received an additional annual fee of $10,000. Also in December 2010, each of our non-employee directors received an annual stock option grant to purchase up to 7,500 shares of common stock in respect of their service as directors for that year. Such stock options will vest in full upon the first anniversary of issuance and have an exercise price equal to the closing price of our common stock on the date of the grant. |
Data sourced from SEC filings. Last updated: 2026-03-05